Scott B. Ullem Sells 11,250 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock

Edwards Lifesciences Co. (NYSE:EW - Get Free Report) CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares of the company's stock, valued at $2,315,301.36. The trade was a 26.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded up $0.23 during trading on Monday, hitting $76.23. The stock had a trading volume of 3,899,190 shares, compared to its average volume of 4,438,355. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The stock has a market capitalization of $44.96 billion, a price-to-earnings ratio of 11.00, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10. The stock has a 50-day simple moving average of $72.67 and a two-hundred day simple moving average of $69.58.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. On average, equities research analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds have recently added to or reduced their stakes in the business. Crowley Wealth Management Inc. acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $26,000. Millstone Evans Group LLC purchased a new position in Edwards Lifesciences in the fourth quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $30,000. FSA Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter worth about $30,000. Finally, Prospera Private Wealth LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at about $32,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on EW shares. Daiwa America downgraded shares of Edwards Lifesciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 30th. Piper Sandler lifted their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Wolfe Research cut Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. Citigroup raised their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the company a "buy" rating in a research report on Wednesday, December 11th. Finally, Stifel Nicolaus upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and boosted their target price for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of "Hold" and an average target price of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.